



Society for Immunotherapy of Cancer

2018 Year in Review



The Society for Immunotherapy of Cancer (SITC) is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

Established in 1984 • 501(c)(3) not-for-profit organization



Society for Immunotherapy of Cancer

Serving:

- Research scientists
- Physician scientists
- Clinicians
- Patients
- Patient advocates
- Government representatives
- Industry leaders

Mission Statement

It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field.

Vision

SITC aims to make cancer immunotherapy a standard of care and the word “CURE” a reality for cancer patients everywhere.



Letter from the President

For the past 34 years, the Society for Immunotherapy of Cancer (SITC) has worked to improve cancer patient outcomes by bringing together the entire cancer immunology and immunotherapy community, and 2018 was a banner year for all of us. Few more so than past SITC Smalley Award recipients James P. Allison, PhD, and Tasuku Honjo, MD, PhD, for receiving the Nobel Prize in the physiology or medicine category for their discovery of cancer therapy by inhibition of negative immune regulation. What a wonderful acknowledgement of the impact in our field to patients, and for the contributions of these two scientific world leaders. It's a very exciting time to be in the field of cancer immunotherapy!

Recently, dozens of immunotherapy approvals across a variety of cancers have increased treatment options and improved outcomes for many patients. The critical advances in research underscore the need for SITC to be at the forefront of supporting and sharing these developments with researchers, and educating the community at large on using the newly available treatments.

The society has gained more members, hosted the most Annual Meeting attendees, received more submissions to the *Journal for ImmunoTherapy of Cancer* and served more users on our website, SITC Cancer Immunotherapy CONNECT, in 2018 than in any previous year of our history.

This Year in Review shares many of the society's key accomplishments of the past 12 months through the prism of our six strategic initiatives: collaboration, engagement, education and scientific exchange, global impact, science and research, and policy and advocacy. These achievements could not have been made without the tireless contributions of hundreds of members and volunteers to whom SITC is truly thankful.

I hope that you enjoy reading the 2018 Year in Review for SITC and recognize your participation and achievements amongst its pages. Together, we can look forward to even greater achievements in our society's future.

Sincerely,



Lisa H. Butterfield, PhD
SITC President



Strategic initiatives:

- **Collaboration:** Cultivate meaningful relationships with key strategic partners
- **Engagement:** Create a network of cancer immunotherapy stakeholders, providing greater opportunities for engagement and interaction
- **Education and Scientific Exchange:** Serve as the leading resource for information and education on cancer immunotherapy
- **Global Impact:** Advance the science and application of cancer immunotherapy worldwide
- **Policy and Advocacy:** Articulate the society's recommendations and offer expertise about issues impacting cancer immunotherapy in the areas of science and research, regulation and quality
- **Science and Research:** Challenge the thinking and seek the best research in the exploration and development of tumor immunology and cancer immunotherapy

Collaboration

SITC Cancer Immunotherapy connectED Online Collaborations

Highlighting exemplary content from partnering organizations via SITC Cancer Immunotherapy connectED, the society's online learning portal, with the following organizations:




ASCO-SITC Clinical Immuno-Oncology Symposium

A three-day symposium in January 2018, in partnership with the American Society of Clinical Oncology (ASCO), providing education on clinical and translational breakthroughs in immuno-oncology

Collaborative Education Programs

In 2018, SITC collaborated with organizations on **20 programs** covering **six countries** (USA, Italy, France, Germany, Spain, Egypt)



Engagement

SITC Committees and Task Forces: *supporting the strategic plan of the society*

Annual Program; Advances in Cancer Immunotherapy™; Awards Review; Biomarkers (and four subcommittees); Biomarkers and Cancer Immunotherapy Guidelines (and four subcommittees); Combination Therapies; Communications; Early Career Recognition; Education and Training; Executive Council (and Nominating Subcommittee); Finance; *Forward Fund*; Immunoscore Steering; Industry; International; Membership; Policy and Advocacy (and three subcommittees); Publications; Cancer Immune Responsiveness Task Force; Certification Task Force; Pathology Task Force; and SITC Champions.

SITC Professional Interest Communities Launch

Launched in August 2018, SITC Professional Interest Communities engage members with similar professional disciplines and experience opportunity in research, scientific applications and career development discussions

SITC Professional Interest Communities exist in the following categories:

- Clinical Trainee Community
- Graduate Student Community
- International Young Investigator Community
- Post-doctoral Trainee Community
- Women in SITC Community



SITC Volunteer Portal Launched October 2018: Improves the volunteer experience for the

600+ SITC volunteers

New Meet-the-Expert Webinar Series:
features free, half-hour webinars for young investigators to engage with experts in the field about career development topics



21 JOURNAL FOR IMMUNOTHERAPY OF CANCER (JITC) EDITORS

NNA C. PAVLICK, DO; MARIA RESCIGNO, PHD; LICIA RIVOLTI

Elevating Women in the Cancer Immunotherapy Field

The second Women's Reception at SITC 2018: a forum for women discuss important topics, including the advancement of women in the field

Women in SITC Leadership Roles

SITC President: Lisa H. Butterfield, PhD (first woman to serve in this role)

SITC Treasurer: Kim A. Margolin, MD

3 At-Large Directors: Leisha A. Emens, MD, PhD; Kristen Hege, MD; Pamela S. Ohashi, PhD

6 Committee Chairs: Lisa H. Butterfield, PhD; Mary L. Disis, MD, FACP; Kim A. Margolin, MD; Kimberly Shafer-Weaver, PhD; Stefani Spranger, PhD; Sara Warren, PhD

SITC Women's Leadership Institute

In 2018, SITC began planning a Women in Cancer Immunotherapy Network (WIN) Leadership Institute to take place in 2019



ANA ANDERSON, MD; LISA H. BUTTERFIELD, PHD; ALESSANDRA CESANO, MD, PHD; JOLANDA DE VRIES, PHD; SANDRA DEMARIA, MD; LEISHA EMENS, MD, PHD; SILVIA FORMENTI, MD; ELIZABETH A. GRIMM, PHD; NANCY M. HAR

DA, MD; KRISTEN HEGE, MD; MICHELLE KROGGGAARD, PHD; ADA KRUISBEEK, PHD; BEATRIX KOTLAN, PHD; SHERENE LOI, MD, PHD; PAMELA S. OHASHI, PHD; A

Education and Scientific Exchange

2018 Interim Workshops

- Cancer Immune Responsiveness Workshop: brought together researchers to help determine which questions in cancer cell biology must be answered to understand patterns of immune interaction between the host and cancers of different ontology, resulting in five post-workshop working groups to address designated questions
- Immuno-Oncology Biomarkers: State of the Art: featured researchers from a broad representation of the field to identify the next steps for action in immunotherapy biomarker development



SITC Cancer Immunotherapy
CONNECT: *the official
website of the Society for
Immunotherapy of Cancer*

1 million+
page views in 2018

2,000+ resources available
to visitors

Annual Meeting & Pre-Conference Programs (SITC 2018)

- The largest conference solely focused on cancer immunotherapy and leading destination for scientific exchange, education and networking in the cancer immunotherapy field
- In 2018, SITC hosted its first joint workshop with the U.S. Food and Drug Administration:
Immune-modified Response Criteria in Cancer Immunotherapy Clinical Trials

5,000 Attendees

795 Abstracts Submitted
(25% increase over 2017)

125+ Faculty

SITC  **2018**

SITC Cancer Immunotherapy Guidelines

A collection of consensus statements, published in the *Journal for ImmunoTherapy of Cancer* and developed by experts to help oncologists determine when and how to best use immunotherapy to treat their patients

2018: Published Two Manuscripts

- Cutaneous Melanoma (Update)
- Non-Small Cell Lung Cancer

New Guidelines Webinars

In July 2018, SITC launched a new series of webinars dedicated to presentation and discussion of recently published SITC Cancer Immunotherapy Guidelines. The webinars allow clinicians to engage with leading experts in the field, ask questions of treatment recommendations in a specific disease state, guidelines concerning biomarker utilizations and more.



SITC Cancer Immunotherapy connectED: *provides free and easy access to accredited online classes for clinicians, interactive learning activities for patients and enduring materials for researchers*

70+ free online classes,
14 years of enduring materials,
13 disease states
featuring patient-focused cancer
immunotherapy education



Education and Scientific Exchange (cont.)

Advances in Cancer Immunotherapy™ (ACI)

Educational series for clinicians featuring **14 live programs** and two webcasts in 2018 across the United States

ACI Webinars: A new series of quarterly webinars, featuring experts in tumor immunology and cancer immunotherapy who highlight the latest clinical advancements and trends in the field and provide a forum for Q&A




Global Impact

SITC Membership


2018 marked a membership milestone with 2,400+ members for the first time in the society's history

2,400+
member milestone

Membership Totals At-a-Glance



SITC Member Geographic Coverage



Number of Specialties – 31

Corporate Membership Category:

During 2018 SITC Election, members approved new corporate membership category

Corporate members will be grouped the following ways:

- Pharmaceutical Companies (Large, Small, Biotech)
- Technology Companies including Device, Diagnostics
- Investment Firms

2018-19 ACI Series

The global reach of SITC's education portal further expanded the impact of SITC's ACI programs. Housing the ACI programs' online and enduring materials on connectedED provided worldwide access to clinicians, researchers, industry professionals, government employees and patient advocates in the field.

Policy and Advocacy

SITC has greatly increased its efforts on Capitol Hill in the past year, advocating for issues and supporting funding requests for programs that directly affect its members and their ability to improve patient outcomes through cancer immunotherapy. The following are several key issues SITC sought to influence in 2018.

Regulatory

SITC advocated for an **increase in federal funding** for the FDA Oncology Center of Excellence in Fiscal Year 2019

\$15 million to \$20 million

Following acceptance of SITC's proposed language verbatim, the U.S. House and Senate urged the FDA to develop standardized templates for reporting toxicities in cancer immunotherapy clinical trials


Quality

To help ensure the decision by the Centers for Medicare & Medicaid Services to open a National Coverage Analytics for CAR T Therapies does not irreparably hinder access to such FDA-approved treatments, SITC submitted comments urging the Centers to consider **several** key points, **including patient access, innovation and the practice of medicine**

Science and Research

SITC-proposed language accepted verbatim in a pair of reports to advocate on behalf of our members and apprise decision makers of field expert opinions on critical issues affecting any/all aspects of the cancer immunotherapy field, including:

- SITC advocated for a \$2 billion increase for the National Institutes of Health that was enacted into law in September
- The House and Senate urged the National Cancer Institute to prioritize research on the underlying mechanisms of cancer immunotherapy toxicities, using language that was provided directly by SITC



Science and Research

Journal for ImmunoTherapy of Cancer (JITC)

The *Journal for ImmunoTherapy of Cancer* is the society's open access, peer-reviewed online journal.

8.374 – Impact Factor

JITC received its first Journal Impact Factor of 8.374 on June 26

JITC's impact factor ranks the journal in the top **8 percent** of all journals published in the categories of oncology and immunology, making JITC the number one fully open access oncology journal in the 2018 Journal Citation Reports



Submissions Up
More Than **300%**

Annual article submissions to the journal have more than tripled compared to 2017

SITC Sparkathon

Bringing together investigators early in their careers with various backgrounds, degrees and professional experiences to collaboratively address obstacles in the cancer immunotherapy field.

2017 SITC Sparkathon Class: 29 young investigators. Following more than 15 months of work, project findings presented during the 33rd Annual Meeting in November 2018

2018 SITC Sparkathon Class: In September, 28 members of the 2018 SITC Sparkathon Class met to begin their work, which they will present during SITC's 34th Annual Meeting in November 2019



Forward Fund

\$2.2 million

The *Forward Fund* seeks to stimulate the future of science, development and application of cancer immunology and immunotherapy through education and research and has **provided more than \$2.2 million in fellowship awards since 2014**



SITC-Stand Up To Cancer Convergence Scholar Awards

In January, SITC announced support of **Convergence Scholar Awards, a collaboration with Stand Up To Cancer** providing early career scientists training in physical and biomedical sciences to better understand the immune system's response to cancer

Science and Research (cont.)

Immunoscore Validation Project

On May 10, 2018, an international consortium led by the SITC published in *The Lancet* results of a **ground-breaking study** demonstrating the immune system's important role in colon cancer prognosis, featuring:

More than 3,500 patients in 13 countries

The Immunoscore Validation Project showed that the presence of immune cells within a cancerous tumor, quantified as a patient's "Immunoscore," is a significant indicator of a patient's prognosis

SITC Fellowship Awards

In 2018, SITC awarded a trio of young investigators for their applications to the SITC Fellowships.

- **SITC-Bristol-Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship Award** (\$200,000; two years) to David Liu, MD, MPH, MS, Dana-Farber Cancer Institute
- **SITC-AstraZeneca Postdoctoral Cancer Immunotherapy in Combination Therapies Clinical Fellowship Award** (\$100,000; one year) to Bryan D. Choi, MD, PhD, Massachusetts General Hospital and Harvard Medical School
- **SITC-Merck Cancer Immunotherapy Clinical Fellowship Award** (\$100,000; one year) to Kelly G. Paulson, MD, PhD, Fred Hutchinson Cancer Research Center
- **SITC-Melanoma Research Alliance (MRA) Young Investigator Award in Immune-Related Adverse Events Associated with Immunotherapy Award:** In October, SITC and MRA sought applicants for a new, \$225,000 three-year fellowship. The award seeks to identify solutions for melanoma patients to overcome immune-mediated adverse events.

White Papers

3 SITC white papers published in 2018

- Chimeric Antigen Receptor (CAR) T Therapies for the Treatment of Hematologic Malignancies: Clinical Perspective and Significance
- Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
- Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology – Society for Immunotherapy of Cancer Statement

33 Abstract Travel Awards

In celebration of the society's 33rd year of advancing cancer immunotherapy worldwide, **SITC presented 33 abstract travel awards to young investigators** recognizing excellence in novel research





Society for Immunotherapy of Cancer

Join the Discussion



Twitter: [@sitcancer](https://twitter.com/sitcancer)



LinkedIn: [linkedin.com/company/381116](https://www.linkedin.com/company/381116)



Facebook: facebook.com/sitcancer



YouTube: youtube.com/sitcancer



sitcancer.org